A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Status:
Recruiting
Trial end date:
2026-07-05
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two
portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory
B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt
lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory
mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or
targeted drug therapy will be enrolled.